High Content Screening

#Academic #Analysis #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Metabolomics #Microbiome #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Metabolon and DNA Genotek collaborate on microbiome sampling solution for metabolomics

25 June 2020 Metabolon and DNA Genotek have teamed up to create OMNImet-GUT, said to be the first device for in-home collection and ambient-temperature storage and shipping of faecal samples for metabolomics, to the research market. “For years, our customers from across biopharma, academia and… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Dotmatics acquires BioBright to accelerate laboratory data automation

25 June 2020 Dotmatics has agreed to acquire BioBright, an expert in automating the flow of data from laboratory instruments to a secure cloud. BioBright’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardise and analyse crucial experimental data… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News

#Animal models #High Content Screening #Regulatory #RNA #Stem cells

Research highlights public desire for animal alternatives in research

24 June 2020 A survey has revealed that 93.4% of respondents think more needs to be done to replace and reduce the use of animals in testing and research. The study by independent scientific research charity FRAME (Fund for the Replacement of Animals in Medical Experiments), also found that over half think… Read More

#News #Regulatory

#Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Precision medicine #RNA

Symbiosis to manufacture COVID-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Epidarex announces £100 million UK venture fund to back life science firms

22 June 2020 Epidarex Capital, an international finance firm, has launched a £102 million fund in Edinburgh to invest in emerging life sciences businesses. The fund will build new life science companies using world-class research and innovation from emerging hubs across the UK, including university spinouts. Typical initial investments… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Regulatory #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

CatalYm to present data on immunotherapy of cancer at AACR Annual Meeting

19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Pharmacology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago

AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More

#Covid-19 #News

#Academic #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Mobidiag receives second tranche of financing from European Investment Bank

17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Clinical specialities #Clinical trials #High Content Screening

AstraZeneca to present new data in treating type-2 diabetes

11 June, 2020 The British-Swedish multinational is to present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, taking place June 12-26. According to AstraZeneca, the data to be presented is among 23 accepted… Read More

#News

#Drug development #Drug discovery #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #RNA #Screening

New antibody internalization advanced screening method provides greater speed & insight

New antibody internalization advanced screening method provides greater speed & insight 26 May 2020 Sponsored by Sartorius Researchers abilities to improve the breadth of therapeutic antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody… Read More

#Editor's Choice #Resources

#Biomarkers #Clinical trials #Drug targets #Genomics #High Content Screening #Precision medicine

Repurposing drug candidates identified to help increase Covid-19 survival rate

UK headquartered AI precision medicine company PrecisionLife has identified 59 repurposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate of patients who develop sepsis while suffering from severe Covid-19. Data scientists from PrecisionLife used the company’s proprietary AI enabled precision… Read More

#Covid-19 #News

#Business #Clinical specialities #Clinical trials #High Content Screening #Immunology #Immunology / Virology & Vaccines #RNA

Agreement for research grade bioreagents for SARS-CoV-2 vaccine

GeoVax Labs, a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced on April 30 that Beijing- and Philadelphia-based Sino Biological, will be its exclusive supplier of SARS-CoV-2 (Covid-19) bioreagent research products. Under the terms of the agreement, Sino Biological will provide… Read More

#Covid-19 #News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Precision medicine #RNA

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate

Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 - Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More

#Exclusive Content